IDH1 and acute myeloid leukemia: Ivosidenib was approved in 2018 for the treatment of patients with R/R AML harboring IDH1 mutations and subsequently in 2019 for the treatment of newly diagnosed AML who are ≥ 75 years of age or are ineligible for intensive chemotherapy with a susceptible IDH1 mutation [16, 17].